Amicus Therapeutics Inc (FOLD)
10.61
+0.27
(+2.61%)
USD |
NASDAQ |
Apr 19, 16:00
10.61
0.00 (0.00%)
After-Hours: 20:00
Amicus Therapeutics Cash from Financing (TTM): 61.68M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 61.68M |
| September 30, 2023 | 54.02M |
| June 30, 2023 | 15.85M |
| March 31, 2023 | -7.134M |
| December 31, 2022 | -7.463M |
| September 30, 2022 | -8.124M |
| June 30, 2022 | 193.55M |
| March 31, 2022 | 195.09M |
| December 31, 2021 | 212.07M |
| September 30, 2021 | 233.72M |
| June 30, 2021 | 271.32M |
| March 31, 2021 | 273.17M |
| December 31, 2020 | 262.86M |
| September 30, 2020 | 244.50M |
| June 30, 2020 | 6.313M |
| March 31, 2020 | 198.63M |
| December 31, 2019 | 217.50M |
| September 30, 2019 | 214.67M |
| June 30, 2019 | 360.95M |
| March 31, 2019 | 171.58M |
| December 31, 2018 | 450.78M |
| September 30, 2018 | 457.28M |
| June 30, 2018 | 560.66M |
| March 31, 2018 | 544.11M |
| December 31, 2017 | 247.43M |
| Date | Value |
|---|---|
| September 30, 2017 | 390.89M |
| June 30, 2017 | 180.34M |
| March 31, 2017 | 273.12M |
| December 31, 2016 | 272.72M |
| September 30, 2016 | 122.55M |
| June 30, 2016 | 136.41M |
| March 31, 2016 | 286.33M |
| December 31, 2015 | 290.89M |
| September 30, 2015 | 389.39M |
| June 30, 2015 | 358.25M |
| March 31, 2015 | 143.33M |
| December 31, 2014 | 139.18M |
| September 30, 2014 | 70.21M |
| June 30, 2014 | 47.75M |
| March 31, 2014 | 29.40M |
| December 31, 2013 | 29.38M |
| September 30, 2013 | 0.162M |
| June 30, 2013 | 18.11M |
| March 31, 2013 | 17.80M |
| December 31, 2012 | 81.48M |
| September 30, 2012 | 80.70M |
| June 30, 2012 | 62.55M |
| March 31, 2012 | 62.97M |
| December 31, 2011 | -0.934M |
| September 30, 2011 | 27.11M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-8.124M
Minimum
Sep 2022
360.95M
Maximum
Jun 2019
157.54M
Average
198.63M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
| TG Therapeutics Inc | 72.70M |
| Geron Corp | 362.02M |
| Vanda Pharmaceuticals Inc | -- |
| Fate Therapeutics Inc | 0.085M |
| Editas Medicine Inc | 118.04M |